Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
10.06
-0.30 (-2.90%)
At close: Feb 27, 2026
22.68%
Market Cap 2.83B
Revenue (ttm) 3.82M
Net Income (ttm) -477.47M
Shares Out 281.53M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,102,287
Average Volume 451,277
Open 10.02
Previous Close 10.36
Day's Range 9.60 - 10.20
52-Week Range 6.09 - 14.10
Beta 0.17
RSI 38.80
Earnings Date Feb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 36
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

In 2025, Vicore Pharma Holding AB's revenue was 3.82 million, a decrease of -96.51% compared to the previous year's 109.35 million. Losses were -477.47 million, 183.1% more than in 2024.

Financial Statements

News

There is no news available yet.